Skip to content
Catalyst

PapersPMID:37767399

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.

Frontiers in pharmacology2023The record ↗

findings
5
compound
1
endpoints
5
no difference found
4
PMID:37767399
  1. Finding, insufficient evidencelowersLDL cholesterol
  2. Finding, moderate evidenceno difference foundBody mass index
  3. Finding, moderate evidenceno difference foundWaist-to-hip ratio
  4. Finding, limited evidenceno difference foundAlanine aminotransferase
  5. Finding, limited evidenceno difference foundAspartate aminotransferase
  • Decreases LDL cholesterol

    insufficientreplicated ×2

    “Compared with model group, the resveratrol group manifested a significant reducing effect on LDL-C level [SMD = −2.01, 95% CI (−2.77, −1.25), p < 0.0001] (Supplementary Figure S3A A).”
    Study
    animal · not in humans
    Participants
    208
    Effect
    −2.01 standardised mean difference, 95% CI −2.77 to −1.25
    Dose studied
    20-400 mg/kg, 4-20 weeks, pooled across studies
    Population
    rodents with diet-induced NAFLD models, resveratrol vs model/control group, preclinical meta-analysis, 13 studies, 208 animals

What did not

  • “The result indicated that there was just the trend of decrease but no significance after treatment with resveratrol compared with placebo in BW [SMD = − 0.08, 95% CI (−0.35, 0.18), p = 0.544], BMI [SMD = − 0.07, 95% CI (−0.33, 0.20), p = 0.633], WC [SMD = −0.73, 95% CI (−1.97, 0.51), p = 0.249] and WHR [SMD = −0.12, 95% CI (−0.40, 0.16), p = 0.405] (Supplementary Figures S14, 15).”
    • Study
      meta-analysis
      Effect
      −0.07 standardised mean difference, 95% CI −0.33 to 0.2
      Dose studied
      300-3,000 mg/day, 8-24 weeks, pooled across trials
      Population
      adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
    • Study
      meta-analysis
      Effect
      −0.12 standardised mean difference, 95% CI −0.4 to 0.16
      Dose studied
      300-3,000 mg/day, 8-24 weeks, pooled across trials
      Population
      adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
  • “Interestingly, the result suggested that there was no significant efficacy of resveratrol on ALT level in NAFLD patients [SMD = −0.16, 95% CI (−0.67, 0.35), p = 0.542], nor was the efficacy in AST [SMD = −0.39, 95% CI (−0.95, 0.16), p = 0.167].”
    • Study
      meta-analysis
      Effect
      −0.16 standardised mean difference, 95% CI −0.67 to 0.35
      Dose studied
      300-3,000 mg/day, 8-24 weeks, pooled across trials
      Population
      adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
    • Study
      meta-analysis
      Effect
      −0.39 standardised mean difference, 95% CI −0.95 to 0.16
      Dose studied
      300-3,000 mg/day, 8-24 weeks, pooled across trials
      Population
      adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs

Study record

Design
meta-analysis
Species
mixed
Population
27 preclinical rodent studies (Sprague-Dawley rats, C57BL/6 mice, Wistar rats, Obese Zucker rats) with NAFLD models (high-fat diet or methionine-choline-deficient diet), and 5 randomized controlled trials in adult patients diagnosed with nonalcoholic fatty liver disease (NAFLD)
Participants
216
Comparator
placebo
Duration
not reported
Endpoints measured
41